Example: quiz answers
US-56427 ---------------------------- DOSAGE AND ...

US-56427 ---------------------------- DOSAGE AND ...

Back to document page

Studies (14.1)]. 5.3 : Dyspnea: In clinical trials, about 14% (PLATO and PEGASUS) to 21% (THEMIS) of patients treated with : BRILINTA developed dyspnea. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment but led to study drug discontinuation in 0.9% (PLATO),

  Studies

Download US-56427 ---------------------------- DOSAGE AND ...


Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Advertisement

Related search queries